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Abstract. The clinical utility of amyloid positron emission tomography (PET) has not been fully established. Our aim was
to evaluate the effect of amyloid imaging on clinical decision making in a secondary care unit and compare our results with
a previous study in a tertiary center following the same methods. We reviewed retrospectively 151 cognitively impaired
patients who underwent amyloid (Pittsburgh compound B [PiB]) PET and were evaluated clinically before and after the
scan in a secondary care unit. One hundred and fifty concurrently underwent fluorodeoxyglucose (FDG)-PET. We assessed
changes between the pre- and post-PET clinical diagnosis and Alzheimer’s disease treatment plan. The association between
PiB/FDG results and changes in management was evaluated using χ2 and multivariate logistic regression. Concordance
between classification based on scan readings and baseline diagnosis was 66% for PiB and 47% for FDG. The primary
diagnosis changed after PET in 17.2% of cases. When examined independently, discordant PiB and discordant FDG were
both associated with diagnostic change (p < 0.0001). However, when examined together in a multivariate logistic regression,
only discordant PiB remained significant (p = 0.0002). Changes in treatment were associated with concordant PiB (p = 0.009)
while FDG had no effect on treatment decisions. Based on our regression model, patients with diagnostic dilemmas, a
suspected non-amyloid syndrome, and Clinical Dementia Rating <1 were more likely to benefit from amyloid PET due to a
higher likelihood of diagnostic change. We found that changes in diagnosis after PET in our secondary center almost doubled
those of our previous analysis of a tertiary unit (9% versus 17.2%). Our results offer some clues about the rational use of

















Keywords: Alzheimer’s disease, amyloid, dementia, FDG, PET, PiB32
∗Correspondence to: Pascual Sánchez-Juan, MD, ‘Marqués de
Valdecilla’ University Hospital, Planta Baja Valdecilla Sur, Avda
Marqués de Valdecilla s/n, 39011 Santander (Cantabria), Spain.
Tel.: +34 942202520 /Ext. 73560); E-mail: psanchez@humv.es.
INTRODUCTION 33
Positron emission tomography (PET) tracers allow 34
moderate to frequent amyloid- (A) plaques to be 35
detected in the brain. There is abundant evidence of 36
the relationship between the risk of mild cognitive 37
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impairment (MCI) and progression to Alzheimer’s38
disease (AD) with brain A deposits [1, 2]. Although39
PET amyloid has been included in new proposals40
of research criteria for AD, [3] there are still many41
uncertainties regarding the implications of having42
a positive amyloid scan in absence of the cogni-43
tive symptoms typical of AD. On the other hand,44
there have been documented pathologically proven45
AD cases with negative ante-mortem amyloid PET46
scan [4]. Therefore, amyloid testing should be put in47
context with clinical evaluation and other biomarkers.48
Three amyloid tracers have been approved for49
clinical use, but their cost at present is high and50
there is still insufficient clinical experience [5]. In51
2013, Appropriate Use Criteria (AUC) were pub-52
lished. However, these are recommendations mainly53
based on expert panels [6]. Nowadays, Centers for54
Medicare & Medicaid Services do not provide cov-55
erage for amyloid PET scans due to insufficient56
evidence for health improvement in dementia with57
these techniques [7]. A recent literature review using58
a structured framework developed for the assessment59
of oncological biomarkers concluded that large stud-60
ies assessing clinical utility of amyloid PET were61
needed [8]. Several publications have attempted to62
address this issue; however, many of them come from63
tertiary care centers with selected patients included64
in ongoing research protocols and treated by highly65
specialized neurologists [9–20]. In 2014 we pub-66
lished the experience of University of California San67
Francisco Memory Aging Center (UCSF-MAC) with68
Pittsburgh compound B PET (PiB-PET) [15]. We69
showed that discordance between initial clinical diag-70
nosis and the result of the PET was a major driving71
force of diagnostic changes. However, the agreement72
between clinicians and PET in that center was very73
high and the percentage of patients with diagnostic74
changes after PET was lower than in previous reports.75
One of the caveats of that study was the dubious gen-76
eralizability of some of the findings, particularly to77
less specialized practice settings.78
The purpose of this study was to evaluate the effect79
of PiB-PET and fluorodeoxyglucose (FDG) PET in80
clinical practice in a secondary care memory unit81
attending non-selected patients with cognitive com-82
plaints referred by general practitioners. To achieve83
this, we followed the same design as in our previous84
study at UCSF-MAC, but applied to a less specialized85
setting at University Hospital Marqués de Valdecilla86
(UHMV) in Santander (Northern Spain).87
We hypothesize that there might be substantial dif-88
ferences in the estimation of the clinical effect of PET89
amyloid depending on the particularities of the cen- 90
ter. In a secondary care unit like UHMV, PiB-PET 91
might have higher repercussions on clinical manage- 92
ment and might be more influential for clinicians than 93
in highly specialized tertiary units like UCSF-MAC. 94
MATERIALS AND METHODS 95
Study population 96
We reviewed retrospectively the UHMV Mem- 97
ory Unit database between 2010 and 2015, and out 98
of the 2116 new patients evaluated, we identified 99
151 who underwent FDG-PET and PiB-PET and 100
were assessed clinically before and after the scan. 101
PET scans were performed under research proto- 102
cols evaluating the utility of PiB in the differential 103
diagnosis of AD [21]. Tests were ordered by the treat- 104
ing neurologists when considered to be helpful in 105
their diagnostic workup. Patients with unstable medi- 106
cal comorbidities, brain mass lesions, and significant 107
cerebrovascular disease were not eligible. Before the 108
PET scan all patients underwent an assessment by 109
a neurologist, cognitive testing, and structural neu- 110
roimaging with CT or MRI. CSF AD biomarkers 111
were not available at the time of disclosure of the PET 112
scan results. FDG-PET and PiB-PET results were 113
revealed simultaneously to the neurologist. Clinical 114
diagnosis was made based on best clinical judgment 115
by the attending neurologists. Up to three differential 116
diagnoses could be listed on the “differential diag- 117
nosis,” ranked in order of likelihood. The post-PET 118
visit included a clinical evaluation and review of PET 119
results. Patients’ records were reviewed retrospec- 120
tively by two neurologists (CL and AGS) to determine 121
the use of AD specific medications at the pre- and 122
post-PET visits. 123
PET scan acquisition and interpretation 124
All patients underwent PiB-PET and FDG-PET 125
at the Nuclear Medicine Department of UHMV. 126
11C-PiB synthesis and image acquisition have been 127
described elsewhere [21]. PET scans were visually 128
interpreted by an experienced nuclear medicine spe- 129
cialist (JJB or IB) as positive/negative for cortical PiB 130
uptake. The inter-rater reliability was very high, with 131
a correlation of 93.3% and a kappa coefficient of 0.87 132
(p < 0.001). When a PiB-PET was considered as pos- 133
itive a global subjective estimation of the amyloid 134
load was given (mild, moderate or severe) describ- 135
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were repeated to rule out technical issues, if after rep-137
etition they were still considered as borderline they138
were removed from the analysis. FDG scans were139
rated as consistent with “AD” or its variants (includ-140
ing dementia with Lewy bodies) if hypometabolism141
primarily involved the temporoparietal cortex, pos-142
terior cingulate/precuneus, or occipital cortex. Scans143
were rated as “non-AD” if hypometabolism primar-144
ily involved the frontal or anterior temporal cortex145
(frontotemporal dementia [FTD] pattern) or appeared146
within normal limits. All PET scan ratings were147
performed blinded to clinical data. The clinician in148
charge was given a report including the dichotomous149
classification of each scan and a description of each150
tracer’s spatial binding pattern.151
Standard protocol approvals, registrations,152
and patient consent153
Written informed consent was obtained from all154
patients or surrogates. The study was approved by our155
regional review board for human research (Comité156
Ético de Investigación de Cantabria).157
Data analysis158
Pre-PET clinical diagnoses were divided into “A”159
or “non-A” categories based on the association160
of the clinical syndrome with amyloid pathology161
(Table 1). A diagnoses consisted primarily of typical162
and atypical presentations of AD [22]. Dementia with163
Lewy bodies was also included in the A group due164
to its high degree of co-pathology with AD. The non-165
A category consisted of clinical variants of FTD.166
Amnestic MCI was included in the A category, and167
non-amnestic MCI was considered a non-A diagno-168
sis [23]. In cases with multiple differential diagnosis,169
the first item listed was considered “primary diagno-170
sis”. Patients listed as both A and non-A diagnoses171
on the differential diagnosis were considered “diag-172
nostic dilemmas”. The primary predictor of interest173
was concordance between PET result and clinical174
diagnosis. PiB positive and FDG-AD scans were175
considered concordant with an A diagnosis, while176
PiB negative and FDG-non-AD scans were consid-177
ered concordant with a non-A diagnosis. The main178
outcomes were defined as changes in: 1) primary179
diagnosis, 2) clinical uncertainty and 3) AD treat-180
ment between the pre- and post-PET visits. Change181
in primary diagnosis was defined as a change in182
the first-listed diagnosis from A to non-A or183
vice versa. Change in AD treatment was defined as184
Table 1
Specific diagnoses at baseline
Specific Diagnoses n (%)
A
AD 30 (19.9)
PPA Logopenic Variant 7 (4.6)
AD Frontal 3 (2.0)
Posterior Cortical Atrophy 2 (1.3)
Amnestic MCI 65 (43.0)
Lewy Body Disease 3 (2.0)
Non-A
Non Amnestic MCI 9 (6.0)
Vascular Dementia 2 (1.3)
bvFTD 12 (7.9)
PPA Non Fluent Variant 2 (1.3)




AD, Alzheimer’s disease; PPA, primary progressive aphasia; MCI,
mild cognitive impairment; bvFTD, behavioral variant frontotem-
poral dementia; CBS, corticobasal syndrome. * B12 deficiency,
immune mediated cognitive impairment, psychiatric, systemic
disease.
initiating or discontinuing cholinesterase inhibitors 185
or memantine. Clinical uncertainty was estimated 186
by the percentage of diagnostic dilemmas. We first 187
assessed the relationship between PET results and 188
clinical outcomes separately for PiB and FDG using 189
χ2 or Fisher’s exact test. Next, we performed logistic 190
regression predicting each outcome when accounting 191
for the following predictors: discordant PiB, discor- 192
dant FDG, diagnostic dilemma pre-PET, sex, age at 193
PET <65 years, baseline A diagnosis, and Clinical 194
Dementia Rating (CDR). 195
RESULTS 196
PET scans were ordered by seven different neu- 197
rologists, three of them are experts in behavioral 198
neurology and the remaining four are general 199
neurologists. We compared the degree of clini- 200
cal concordance with PET results and found no 201
statistically significant differences across neurolo- 202
gists (PiB p = 0.48; FDG p = 0.46). Additionally, we 203
stratified the sample comparing the three more experi- 204
enced neurologists in behavioral neurology with the 205
general neurologists without finding differences in 206
concordance (PiB p = 0.88; FDG p = 0.54). The most 207
frequent etiologic subgroup in our cohort was amnes- 208
tic MCI followed by AD (Table 1). In most patients, 209
an A diagnosis was expected before PET. The aver- 210
age age of our patients was relatively young and most 211
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Table 2
Clinical and demographical characteristics
Patient’s characteristics
Age at diagnosis (mean years ± SD) 67.3 ± 8
Sex (females) 56.3%
MMSE (mean ± SD) 24.2 ± 4.5
Diagnostic dilemma 37.7%
Months pre- to post-PET (Mean ± SD) 9.9 ± 10.7
Primary diagnosis (A diagnoses/Non-A 72.8% / 27.2%
diagnoses)
AD treatment (ChEI or memantine) 25.2%
CDR < 1 89.9%
MMSE, Mini-Mental-State Examination; AD, Alzheimer’s dis-
ease; ChEI, cholinesterase inhibitors; CDR, Clinical Dementia
Rating.
Only a quarter of our patients were on AD-drugs213
treatment pre-PET (Table 2). Three PiB-PET scans214
were considered as “equivocal” and removed from215
the analysis.216
Concordance between PET results and clinical217
suspicion218
Overall concordance between classification based219
on scan readings and pre-PET diagnosis was 66.2220
% for PiB and 46.7% for FDG. PiB concordance221
was higher than FDG concordance in typical AD222
(p = 0.05) and in amnestic MCI (p = 0.00002); and223
PiB concordance was higher in AD than in MCI224
(p = 0.03) and in corticobasal syndrome (p = 0.001)225
(Fig. 1A). We found no differences regarding age226
(PiB p = 0.63; FDG p = 017) or CDR (PiB p = 0.94;227
FDG p = 0.25). (Fig. 1B, C). Overall, PiB and FDG228
agreed in classifying 74% of patients.229
Diagnostic changes after PET230
The primary diagnosis changed after PET in 17.2%231
of the patients. Tested separately, discordant PiB and232
discordant FDG results were both strongly associated233
with diagnostic change. In the crude analysis, there234
was a very significant association between patients235
with diagnostic dilemmas pre-PET and changes236
in diagnosis. When including both PET scans as237
predictors in a single logistic regression model,238
diagnostic changes were associated with discordant239
PiB (p = 0.0002) but not discordant FDG (p = 0.14)240
(Table 3). When both scans agreed with clinical241
diagnosis, changes were exceptional (1.5%). On the242
contrary, diagnostic changes were likely performed243
when both scans were discordant with clinical diag-244
nosis (45.6%) or when PiB was discordant but not245
FDG (60%); however, when FDG was discordant246
but PiB agreed with the clinical diagnosis, clinicians 247
tended to relay more on PiB and only changed the 248
diagnosis in 2.9% of cases (Table 4). 249
The full logistic regression model (Table 3) 250
shows that diagnostic dilemmas and discordant 251
PiB remained significantly associated to diagnostic 252
changes after p-value adjustment. Additionally, when 253
a non A syndrome was suspected, this diagnosis was 254
most likely to be changed after PET; the same hap- 255
pened with patients with CDR <1, which is consistent 256
with the fact that 34.6% of all diagnostic changes took 257
place in amnestic MCI patients. 258
Changes in the clinician’s diagnostic confidence 259
The number of diagnostic dilemmas decreased sig- 260
nificantly from 37.7% pre-PET to 15.6% post-PET 261
(p = 0.00002). 262
Treatment changes after PET 263
In 45% of the patients a treatment change took 264
place after PET results. The most common change 265
was the addition of an AD drug (85.3%). FDG results 266
did not influence treatment. However, we found that 267
concordance between PiB-PET and clinical diagno- 268
sis was significantly associated to treatment change 269
(p = 0.006), and these results were also statisti- 270
cally significant in the full logistic regression model 271
(p = 0.009). (Table 5). The main diagnostic group 272
where changes took place was amnestic MCI (47% 273
of treatment changes), of which in 94% consisted in 274
the initiation of an AD drug. 275
Comparison with a tertiary center 276
UCSF-MAC and UHMV study populations had 277
on average a similar age at disease onset (UCSF- 278
MAC 65.0 years versus 67.3 years UHMV) and 279
were also evaluated at early disease stages (UCSF- 280
MAC MMSE 22.7 versus 24.2 UHMV). However, 281
the percentage of AD drug treated patients was higher 282
in UCSF-MAC (46% on cholinesterase inhibitors 283
and 39% on memantine) than in UHMV (75% 284
untreated), and UHMV had a predominance of sus- 285
pected A pathology (72.8% UHMV versus 46% 286
in UCSF-MAC). Another distinction between both 287
study populations is the fact that while MCI was the 288
most frequent diagnostic category in UHMV (49%), 289
it was rare at UCSF-MAC (7%). This is consistent 290
with differences in CDR between both populations 291













C. Lage et al. / Utility of Amyloid and FDG-PET 5
Fig. 1. A) The percentage of concordance between the initial diagnosis and PIB and FDG PET results. PiB concordance was higher than
FDG concordance in typical AD (80% versus 57%, respectively) and in amnestic MCI (57% versus 20%, respectively). PiB concordance
was higher in AD than in MCI (80% versus 57%, respectively) and in corticobasal syndrome (80% versus 0% respectively). We found
no differences regarding age (B) or CDR (C). AD, typical Alzheimer’s disease; PPA, primary progressive aphasia; MCI, mild cognitive
impairment; bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; MMSE, Mini-Mental-State Examination;
CDR, Clinical Dementia Rating.
Table 3
Factors associated with diagnostic changes
Predictors of diagnostic change No diagnostic Diagnostic p Adjusted* p
change (n = 125) % change (n = 26) %
Age < 65 43.2 38.5 0.66 0.46
Female 54.4 65.4 0.30 0.54
Non-A pre-PET syndrome 25.6 34.6 0.35 0.03
Dilemma pre-PET 30.6 72.0 0.0001 0.0005
PiB discordant with clinical syndrome 21.6 92.3 1.6 × 10−12 0.0002
FDG discordant with clinical syndrome 46.8 84.6 0.0004 0.14
CDR < 1 89.4 92.3 0.66 0.05
*Adjusted by all other covariates included in the model CDR, Clinical Dementia Rating.
A common finding with the UCSF-MAC study293
was that clinical concordance with PiB was higher294
than with FDG, a difference that was statistically295
significant for classical forms of AD. Additionally, in 296
both studies PiB results were more determinant for 297
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Table 4
Diagnostic changes according to FDG and PET PiB concordance
to clinical diagnosis
discordant with the FDG, they tended to follow the299
PiB.300
We found that agreement between clinical diag-301
nosis and amyloid PET was lower in UHMV than302
in UCSF-MAC (66.2% versus UCSF-MAC 84%).303
That lower agreement in the secondary center was in304
line with a higher rate of changes in diagnosis after305
PET (UHMV 17.2% versus UCSF-MAC patients306
9%). Likewise, clinical dilemmas reduction was more307
intense in UHMV with a 22.1% reduction after PET308
compared to 8% at UCSF-MAC. Finally, meanwhile309
the influence of PET-PiB over treatment was not sig-310
nificant for the UCSF-MAC patients, there was a clear311
effect on treatment in UHMV, where PET played a312
confirmatory role.313
DISCUSSION314
One of our main findings was that changes in diag-315
nosis after PET in UHMV almost doubled those of316
our previous analysis of the UCSF-MAC patients.317
Percentages referring to diagnostic changes after318
amyloid PET reported in previous studies vary widely319
from 9% to 79%, and similar disparities are found320
when other indicators are analyzed such as influence321
on AD specific treatment or clinicians’ confidence322
in diagnosis [9–20]. These differences are related to323
study design and methodology. In general, site spe-324
cialty studies, like the current work and our previous325
analysis of the UCSF-MAC series, tend to show lower326
clinical repercussion than large multicenter studies.327
For instance, diagnostic changes after PET were esti- 328
mated to be 9%, 19%, 23%, and 23% respectively in 329
uni-center studies [11, 14, 15, 18]; in contrast to larger 330
multi-center studies: 32.6%, 54.6% and 79%, respec- 331
tively [12, 19, 20]. This is in line with preliminary data 332
from the Imaging Dementia Evidence for Amyloid 333
Scanning study (IDEAS), a study organized by the 334
Alzheimer’s Association currently assessing the clin- 335
ical utility of amyloid PET in 674 clinical practices. 336
Interim results from the first 4,000 people scanned 337
show that after amyloid PET results care plans shifted 338
for 67.6 percent of participants (Rabinovici, personal 339
communication). These differences might be related 340
to the fact that in single site studies there could be an 341
overrepresentation of more specialized centers with 342
earlier access to amyloid PET technology diluting 343
this bias in large multicenter studies. 344
Due to the heterogeneity among published studies, 345
the comparison between UHMV and UCSF-MAC, 346
applying the same design and methods, has notable 347
value because it allows a straightforward interpreta- 348
tion and offers clues about the different utility of these 349
tests depending on the context. Different rates in diag- 350
nostic change could be partially explained by the fact 351
that the agreement between clinical diagnosis and 352
amyloid PET, the largest determinant of diagnostic 353
change in both studies, was 17.8% lower in UHMV. 354
The discordance between the clinician’s initial diag- 355
nosis and the result of the scan could be a proxy of 356
the amount of additional information offered by the 357
test. Therefore, in our setting, amyloid PET seems to 358
play a more valuable role than in tertiary units like 359
UCSF-MAC. The differences in discordance between 360
centers might be caused by many factors such as 361
neurologist expertise, methodological differences in 362
clinical workup and diverse patient profile. We did 363
not find significant differences within UHMV neu- 364
rologists. However, there is evident distinctness in 365
the average patient profile attended by each group. 366
Age at onset and disease stage at recruitment time 367
was similar in both studies. However, UCSF-MAC 368
patients were frequently referred for second opinions 369
and for inclusion in research protocols, as reflected by 370
the fact that almost half of them were already treated 371
with AD drugs at recruitment time, and in less than 372
Table 5
Changes in AD treatment in relation to concordance of clinical diagnosis with PET results
AD-treatment change No AD-treatment change p Adjusted p*
PET PiB concordance 77.9% (53/68) 56.6% (47/83) 0.006 0.009
PET FDG concordance 41.8% (28/67) 50.6% (42/83) 0.28 0.17
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half of the cases A pathology was the first suspected373
diagnosis. In UHMV, most patients were referred by374
general practitioners for diagnosis and treatment, AD375
being the most common initial diagnosis. Some of376
the patients’ characteristics reflect the particularities377
of a secondary care center versus a tertiary center378
highly specialized in FTD, like the UCSF-MAC. A379
major difference between both populations is the380
fact that while the most frequent diagnostic category381
in UHMV was MCI, it was almost non-existent at382
UCSF-MAC. This is of special importance because383
patients with CDR <1 of our series were significantly384
more likely to change diagnosis after PET, which is385
in line with the fact that a third of diagnostic changes386
took place in the amnestic MCI patients.387
Changes in treatment were a major clinical output388
of our study. There was a clear effect on treatment in389
UHMV, where PET played a confirmatory role. Thus,390
AD treatments were initiated in many patients, mostly391
in amnestic-MCI, when PET-PiB was positive. This392
pattern has been found also in other studies in which393
clinicians’ decisions to start AD treatments were sup-394
ported by amyloid PET results [20]. In contrast, the395
influence of PET-PiB on treatment was not signif-396
icant for the UCSF-MAC patients. In both studies,397
PET scan information helped to increase diagnostic398
certainty indirectly estimated by a decrease in the399
percentage of patients with clinical dilemmas; again,400
this effect was more intense in UHMV compared to401
UCSF-MAC. The increase in the clinician’s confi-402
dence in diagnosis is a constant finding across studies403
assessing the clinical utility of amyloid PET. In our404
study, increased diagnostic confidence facilitated a405
more proactive attitude towards AD treatment. There406
are evidences in the literature supporting that early407
AD treatment might be beneficial [24, 25]. Addition-408
ally, many of our patients are illiterate and they have409
a very basic premorbid functional level, therefore,410
sometimes it is not straightforward to estimate a clear411
loss of function, as this could be evident for the fam-412
ily relatively late. In these cases, in which functional413
impairment is doubtful, a positive amyloid test might414
reinforce the decision to start treatment.415
A common finding with the UCSF-MAC study416
was that clinical concordance with PiB was higher417
than with FDG, a statistically significant difference418
for classical forms of AD. Additionally, in both stud-419
ies PiB results were more determinant for clinicians420
than FDG, so when the PiB results were discordant421
with the FDG, they tended to follow the PiB. This is422
supported by the fact that in our full logistic regres-423
sion model, the clinical discordance with the results424
of the FDG-PET was not significantly associated with 425
diagnostic change, despite a strong association in 426
the univariate analysis. The discordance with FDG 427
was not associated with treatment changes in any of 428
the studies either. Our naturalistic approach is not 429
suitable for a direct comparison between both PET 430
tracers. Therefore, these results, must be taken with 431
caution. Since we have no pathology data available 432
we are only reflecting clinician’s behavior and not 433
the true sensitivity or specificity of the test. However, 434
from a qualitative point of view we consider that FDG 435
PET could be very helpful in the diagnosis of compli- 436
cated cases, especially in those in which co-pathology 437
is suspected. 438
Amyloid PET tracers approved for clinical use 439
are still very expensive, and therefore it is relevant 440
to provide clinicians with guidelines for a rational 441
and cost-effective use. The AUC proposes that amy- 442
loid PET should be used in patients with uncertain 443
diagnosis, in three clinical scenarios: 1) MCI, 2) atyp- 444
ical dementia, and 3) early-onset dementia. Our data 445
strongly support the indication of testing for MCI 446
patients. On the one hand, we found the highest level 447
of discordance in this group and consequently the 448
highest levels of diagnostic changes; on the other 449
hand, treatment changes were more frequent after 450
concordant PET results in MCI, a population where 451
the test mainly played a confirmatory role in deci- 452
sions regarding the initiation of treatment. We found 453
only partial evidence supporting the second scenario 454
as the degree of discordance was significantly higher 455
in an atypical syndrome like corticobasal syndrome 456
(p = 0.001) compared to typical AD, indicating that 457
amyloid PET could be of more help in these patients. 458
Our study might be underpowered for detecting sig- 459
nificant difference in other atypical cases where 460
numbers were small for the specific categories. We 461
did not find any differences between patient age at 462
study entry and clinical discordance with the PET 463
results. However, most of the patients were relatively 464
young, as clinicians are aware of age-related decrease 465
in specificity, so we were unable to contrast the utility 466
of the test with older patients [26]. 467
Our data offers some hints of the patient’s pro- 468
file in which the test would offer more information. 469
In addition to PiB discordance, the main predictors 470
of diagnostic change in the full regression model 471
were diagnostic dilemmas, initial diagnosis of non 472
A syndrome and CDR <1. Therefore, according to 473
our results, the archetypical patient in which the test is 474
more likely to be helpful is a relatively young patient 475
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early disease stages, in which the main suspected477
diagnosis is not AD, though AD cannot be ruled out478
in the differential diagnosis.479
The study has some caveats. PET images were not480
rated using semiquantitative methods. However, in a481
previous study we have compared a semiquantitative482
analysis, using a SUVR threshold, versus a subjective483
assessment method and we found a high concordance484
between both methods [21]. The retrospective design485
precludes a direct estimation of clinicians’ change in486
diagnostic confidence; we attempted to quantify this487
factor by the degree of clinical dilemma reduction488
after the test. Additionally, despite our multivariate489
analysis, we cannot completely separate the influence490
of PiB and FDG or control for the evolution of clinical491
symptoms or the availability of additional data at the492
post-PET visit. In our study, we have no neuropatho-493
logical data; therefore, we are unable to contrast clin-494
ical or PET results with a gold standard. Our design495
follows a naturalistic approach, attempting to observe496
and quantify clinician behavior in real practice.497
This study represents a rare opportunity to assess,498
using the same methodology, the differential effect499
of amyloid PET between a secondary and a tertiary500
center, supporting the hypothesis that this test plays501
a more relevant role in a less specialized context.502
There is a bias in scientific literature toward stud-503
ies coming from tertiary centers, but we think that504
our results, evaluating the clinical repercussion of505
amyloid PET in a secondary care memory unit, are506
more likely generalizable to an average clinical prac-507
tice. Large prospective multicentric studies like the508
ongoing IDEAS including centers with diverse char-509
acteristics are still needed to robustly evaluate the510
clinical contribution of amyloid PET.511
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